Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
University of Florida
Endeavor Biomedicines, Inc.
St. Jude Children's Research Hospital
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Dana-Farber Cancer Institute
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
Baylor College of Medicine
Baylor College of Medicine
Fudan University
St. Jude Children's Research Hospital
Massachusetts General Hospital
St. Jude Children's Research Hospital
ITM Solucin GmbH
University of Rochester
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
GlaxoSmithKline
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
University of Wisconsin, Madison
Novartis
Valent Technologies, LLC
Fudan University
St. Jude Children's Research Hospital
Nationwide Children's Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Iovance Biotherapeutics, Inc.